SecBot SecBot
SECBOTREPLAY Home › Report › OCGN

OCGN · Ocugen signed a binding term sheet with Roots Pharmaceutical to license…

Ocugen, Inc. · 8-K filed Jul 13, 2026 at 08:30 ET

At the news

BULLISHIMPACT 6/10

8-K filed Jul 13, 2026 at 08:30 ET

Ocugen signed a binding term sheet with Roots Pharmaceutical to license OCU400 modifier gene therapy for retinitis pigmentosa in the MENA region. The deal includes upfront/near-term milestones up to $4 million, cumulative sales milestones up to $255 million, and a 22% royalty on net sales, with Ocugen manufacturing commercial supply. A definitive agreement is expected within 90 days, and the Phase 3 liMeliGhT trial topline readout is expected in Q1 2027.

  • Binding term sheet signed with Roots Pharmaceutical for OCU400 license in MENA region
  • Upfront and near-term development milestones up to $4 million
  • Cumulative sales milestones up to $255 million
  • 22% royalty on net sales

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access